**AFLURIA® QUADRIVALENT**  
(Influenza Vaccine)  
Coding and Billing


**Code for the AFLURIA QUADRIVALENT vaccine administered**

<table>
<thead>
<tr>
<th>2020-2021 NDC Carton¹</th>
<th>2020-2021 NDC Unit-of-Use¹</th>
<th>Presentation and Indication¹</th>
<th>Product Billing CPT Code</th>
<th>Description¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>33332-220-20</td>
<td>33332-220-21</td>
<td>0.25 mL pre-filled syringe (6-35 months)</td>
<td>90685</td>
<td>Influenza vaccine, quadrivalent (IIV4), split virion, contains no preservative, 0.25 mL dosage, for intramuscular use</td>
</tr>
<tr>
<td>33332-320-01</td>
<td>33332-320-02</td>
<td>0.5 mL pre-filled syringe (36 months and older)</td>
<td>90686</td>
<td>Influenza vaccine, quadrivalent (IIV4), split virion, contains no preservative, 0.5 mL dosage, for intramuscular use</td>
</tr>
<tr>
<td>33332-420-10</td>
<td>33332-420-11</td>
<td>5 mL multi-dose vial* (6-35 months)</td>
<td>90687 (0.25 mL dose)</td>
<td>Influenza vaccine, quadrivalent (IIV4), split virion, 0.25 mL dosage, for intramuscular use</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5 mL multi-dose vial* (36 months and older)</td>
<td>90688 (0.5 mL dose)</td>
<td>Influenza vaccine, quadrivalent (IIV4), split virion, 0.5 mL dosage, for intramuscular use</td>
</tr>
</tbody>
</table>

*No more than 10 doses (0.25 mL or 0.5 mL) should be withdrawn from the AFLURIA QUADRIVALENT multi-dose vial. NDC=National Drug Code

Note: Some payers may require use of NDC codes. If so, determine if the payer requires the carton NDC or the unit-of-use NDC, and then determine if the payer requires the 10-digit or 11-digit format. If 11-digit, add a leading zero to the middle section of numbers.

**Code for the administration of AFLURIA QUADRIVALENT**

Report the appropriate administration code in addition to the CPT code for AFLURIA QUADRIVALENT.² For most payers, use the appropriate CPT code based on age and counseling provided. Note: Medicare (and some other payers) requires use of the Healthcare Common Procedure Coding System (HCPCS) code, G0008, for administration of preventive vaccines, including influenza, regardless of age.

Include the appropriate International Classification of Diseases, Tenth Revision (ICD-10) diagnosis code

Report the ICD-10 diagnosis code, Z23, indicating an encounter for vaccine administration. The ICD-10 diagnosis code should be linked to both the vaccine and the administration code.³

**Determine if modifier 25 is appropriate**

When AFLURIA QUADRIVALENT is administered on the same date as a significant and separately identifiable Evaluation and Management (E/M) visit, apply modifier 25 to the E/M CPT code, denoting a “significant and separately identifiable” service from the vaccine and vaccine administration service.⁵

Please see Important Safety Information on next page, and the US full Prescribing Information for AFLURIA QUADRIVALENT here.

**Questions?**

Call flu360 | Support 855-358-8966, option 3

---

¹Note: Some payers may require use of NDC codes. If so, determine if the payer requires the carton NDC or the unit-of-use NDC, and then determine if the payer requires the 10-digit or 11-digit format. If 11-digit, add a leading zero to the middle section of numbers.

²For most payers, use the appropriate CPT code based on age and counseling provided. Note: Medicare (and some other payers) requires use of the Healthcare Common Procedure Coding System (HCPCS) code, G0008, for administration of preventive vaccines, including influenza, regardless of age.

³Include the appropriate International Classification of Diseases, Tenth Revision (ICD-10) diagnosis code

⁴Report the ICD-10 diagnosis code, Z23, indicating an encounter for vaccine administration. The ICD-10 diagnosis code should be linked to both the vaccine and the administration code.

⁵Determine if modifier 25 is appropriate

When AFLURIA QUADRIVALENT is administered on the same date as a significant and separately identifiable Evaluation and Management (E/M) visit, apply modifier 25 to the E/M CPT code, denoting a “significant and separately identifiable” service from the vaccine and vaccine administration service.
AFLURIA® QUADRIVALENT (Influenza Vaccine)

Important Safety Information

INDICATION

AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. AFLURIA QUADRIVALENT is approved for use in persons 6 months of age and older.

CONTRAINDICATIONS

• Severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine.

WARNINGS AND PRECAUTIONS

• If Guillain–Barré Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination, the decision to give AFLURIA QUADRIVALENT should be based on careful consideration of the potential benefits and risks.
• Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.
• Immunocompromised persons may have a diminished immune response to AFLURIA QUADRIVALENT.

ADVERSE REACTIONS

• In adults 18 through 64 years, the most commonly reported injection-site adverse reactions when administered by needle and syringe was pain (≥40%). The most common systemic adverse events were myalgia and headache (≥20%).
• In adults 65 years of age and older, the most commonly reported injection-site adverse reaction when administered by needle and syringe was pain (≥20%). The most common systemic adverse event was myalgia (≥10%).
• In children 5 through 8 years, the most commonly reported injection-site adverse reactions when administered by needle and syringe were pain (≥50%), redness and swelling (≥10%). The most common systemic adverse event was headache (≥10%).
• In children 9 through 17 years, the most commonly reported injection-site adverse reactions when administered by needle and syringe were pain (≥50%), redness and swelling (≥10%). The most common systemic adverse events were headache, myalgia, and malaise and fatigue (≥10%).
• In children 6 months through 35 months of age, the most commonly reported injection-site reactions were pain and redness (≥20%). The most common systemic adverse events were irritability (≥30%), diarrhea and loss of appetite (≥20%).
• In children 36 through 59 months of age, the most commonly reported injection-site reactions were pain (≥30%) and redness (≥20%). The most commonly reported systemic adverse events were malaise and fatigue, and diarrhea (≥10%).

The safety experience with AFLURIA (trivalent formulation) is relevant to AFLURIA QUADRIVALENT because both vaccines are manufactured using the same process and have overlapping compositions:
• In adults 18 through 64 years of age, the most commonly reported injection-site adverse reactions with AFLURIA (trivalent formulation) when administered by the PharmaJet Stratis Needle-Free Injection System were tenderness (≥80%), swelling, pain, redness (≥60%), itching (≥20%) and bruising (≥10%). The most common systemic adverse events were myalgia, malaise (≥30%), and headache (≥20%).

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus USA Inc. at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Please see full Prescribing Information for AFLURIA QUADRIVALENT here.

AFLURIA is a registered trademark of Seqirus UK Limited or its affiliates. PharmaJet® and STRATIS® are registered trademarks of PharmaJet.

Information on reimbursement is provided as a courtesy. Due to the rapidly changing nature of the law, Medicare payment policy, and/or reliance on information provided by outside sources, the information provided herein does not constitute a guarantee or warranty that reimbursement will be received or that the codes identified herein are or will remain applicable. This information is provided “as is” and without any other warranty or guarantee, expressed or implied, as to completeness or accuracy, or otherwise.

Providers must confirm or clarify coding and coverage from their respective payers, and are responsible for accurate reporting of products in accordance with particular payer requirements.


flu360™, AFLURIA® QUADRIVALENT, and WE’VE GOT FLU COVERED™ are trademarks of Seqirus UK Limited or its affiliates. Manufactured by: Seqirus Inc., 475 Green Oaks Parkway, Holly Springs, NC 27540, USA Distributed by: Seqirus USA Inc., 25 Deforest Avenue, Summit, NJ 07901, USA ©2020 Seqirus USA Inc. July 2020 US/FLU360/0620/0030a